Literature DB >> 10383855

Increased expression of insulin-like growth factor-I in serum and liver after recombinant human growth hormone administration in thermally injured rats.

M G Jeschke1, M T Chrysopoulo, D N Herndon, S E Wolf.   

Abstract

BACKGROUND: Recombinant human growth hormone (rhGH) has been shown to modulate the hypermetabolic response and the hepatic acute-phase response after thermal injury. In vitro studies, however, demonstrated that rhGH activates insulin-like growth factor-I (IGF-I) gene transcription and production, suggesting that rhGH may exert some of its effects indirectly through IGF-I stimulation. The purpose of this study was to determine the effects of rhGH on serum and hepatic IGF-I in thermally injured rats.
METHODS: Sprague-Dawley rats (56 males) receiving a 60% TBSA third-degree scald burn were randomly divided to receive either rhGH (2.5 mg/kg/day im) or saline (control). Rats were sacrificed on postburn days 1, 2, 5, and 7 and serum IGF-I, hepatic IGF-I mRNA, and IGF-I protein concentration were measured. The physiologic response to changes in IGF-I levels was evaluated by measuring hepatocyte proliferation, total liver protein concentration, and muscle dry/wet weights.
RESULTS: Serum IGF-I was increased from postburn day 1 through day 7 in rats receiving rhGH compared to controls (P < 0.05). Hepatic IGF-I mRNA and IGF-I protein expression were increased from day 1 to 7 after burn in animals receiving rhGH when compared to controls (P < 0.05). Recombinant hGH increased hepatocyte proliferation at 5 days and total liver protein concentration at 5 and 7 days postburn compared to controls (P < 0.05). Muscle dry/wet weights increased in rats receiving rhGH at 7 days after burn compared to controls (P < 0.05).
SUMMARY: Liver and serum IGF-I levels decreased after a thermal injury. Recombinant hGH attenuated this decrease by stimulating hepatic IGF-I expression. Increases in IGF-I were associated with increases in hepatocyte proliferation and protein concentration in liver and muscle.
CONCLUSION: We suggest that rhGH modulates the hypermetabolic response through IGF-I stimulation in the hepatic parenchyma. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10383855     DOI: 10.1006/jsre.1999.5623

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  8 in total

Review 1.  The GH/IGF-1 system in critical illness.

Authors:  Itoro E Elijah; Ludwik K Branski; Celeste C Finnerty; David N Herndon
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2011-10       Impact factor: 4.690

Review 2.  What, how, and how much should patients with burns be fed?

Authors:  Felicia N Williams; Ludwik K Branski; Marc G Jeschke; David N Herndon
Journal:  Surg Clin North Am       Date:  2011-06       Impact factor: 2.741

Review 3.  Postburn Hypermetabolism: Past, Present, and Future.

Authors:  Marc G Jeschke
Journal:  J Burn Care Res       Date:  2016 Mar-Apr       Impact factor: 1.845

4.  Burn and starvation increase programmed cell death in small bowel epithelial cells.

Authors:  M G Jeschke; M A Debroy; S E Wolf; S Rajaraman; J C Thompson
Journal:  Dig Dis Sci       Date:  2000-02       Impact factor: 3.199

5.  Nutritional and Pharmacological Modulation of the Metabolic Response of Severely Burned Patients: Review of the Literature (Part II)*.

Authors:  B S Atiyeh; S W A Gunn; S A Dibo
Journal:  Ann Burns Fire Disasters       Date:  2008-09-30

Review 6.  The hepatic response to thermal injury: is the liver important for postburn outcomes?

Authors:  Marc G Jeschke
Journal:  Mol Med       Date:  2009-04-10       Impact factor: 6.354

Review 7.  The hypermetabolic response to burn injury and interventions to modify this response.

Authors:  Felicia N Williams; David N Herndon; Marc G Jeschke
Journal:  Clin Plast Surg       Date:  2009-10       Impact factor: 2.017

Review 8.  Recombinant human growth hormone for treating burns and donor sites.

Authors:  Roelf S Breederveld; Wim E Tuinebreijer
Journal:  Cochrane Database Syst Rev       Date:  2014-09-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.